SEC Comment Letter 0000000000-24-009362 to CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc.
Date: Aug. 15, 2024 · CIK: 0001501989 · Accession: 0000000000-24-009362
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281433
Letter
August 15, 2024 Chris Ogden Chief Financial Officer CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, CA 94080 Re:CytomX Therapeutics, Inc. Registration Statement on Form S-3 Filed August 9, 2024 File No. 333-281433 Dear Chris Ogden: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Mark Roeder
Show Raw Text
August 15, 2024
Chris Ogden
Chief Financial Officer
CytomX Therapeutics, Inc.
151 Oyster Point Blvd., Suite 400
South San Francisco, CA 94080
Re:CytomX Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 9, 2024
File No. 333-281433
Dear Chris Ogden:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Mark Roeder